RxDoctor Payments DataLook up a doctor →

David Britt, MD

Internal Medicine · Louisville, KYNPI 1265424824

Payments from drug & device makers

$15,638in general payments, 2019–2025

Across 932 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amgen$2K
  • Pfizer$1K
  • Lilly USA, LLC$620
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$15,625100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,638 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$84,074
Medicare patients
311
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$80,453
FarxigaDapagliflozin Propanediol66$65,525
MounjaroTirzepatide59$62,103
TrulicityDulaglutide44$59,942
JardianceEmpagliflozin72$54,662
OzempicSemaglutide29$39,730
XareltoRivaroxaban34$35,074
RybelsusSemaglutide14$27,017
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$24,717
Tresiba Flextouch U-100Insulin Degludec21$16,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,696
MyrbetriqMirabegron21$9,271
Combivent RespimatIpratropium/Albuterol Sulfate11$8,431
SynthroidLevothyroxine Sodium119$7,723
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl53$7,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$620$122,045103 claims
PfizerEliquis$1,452$80,453102 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,778$71,89777 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$536$69,18495 claims
Novo NordiskOzempic, Rybelsus$2,037$66,74743 claims
Johnson & JohnsonXarelto$470$35,07434 claims
GSKTrelegy Ellipta$485$9,69611 claims
Astellas Pharma US IncMyrbetriq$219$9,27121 claims
AbbVieSynthroid$2,563$7,723119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →